Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls

dc.creatorEmmerich, J
dc.creatorRosendaal, FR
dc.creatorCattaneo, M
dc.creatorMargaglione, M
dc.creatorDe Stefano, V
dc.creatorCumming, T
dc.creatorArruda, V
dc.creatorHillarp, A
dc.creatorReny, JL
dc.date2001
dc.dateSEP
dc.date2014-11-15T09:32:39Z
dc.date2015-11-26T17:19:18Z
dc.date2014-11-15T09:32:39Z
dc.date2015-11-26T17:19:18Z
dc.date.accessioned2018-03-29T00:07:00Z
dc.date.available2018-03-29T00:07:00Z
dc.identifierThrombosis And Haemostasis. F K Schattauer Verlag Gmbh, v. 86, n. 3, n. 809, n. 816, 2001.
dc.identifier0340-6245
dc.identifierWOS:000170992600014
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/79018
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/79018
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/79018
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1282874
dc.descriptionFactor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% Cl; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%,) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, die odds ratio for VTE was 10.25 18.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups.
dc.description86
dc.description3
dc.description809
dc.description816
dc.languageen
dc.publisherF K Schattauer Verlag Gmbh
dc.publisherStuttgart
dc.publisherAlemanha
dc.relationThrombosis And Haemostasis
dc.relationThromb. Haemost.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectfactor V Leiden
dc.subjectfactor II G20210A
dc.subjectdeep vein thrombosis
dc.subjectoral contraceptive
dc.subjectActivated Protein-c
dc.subjectDeep-vein Thrombosis
dc.subjectPoor Anticoagulant Response
dc.subjectPulmonary-embolism
dc.subject3'-untranslated Region
dc.subjectFamilial Thrombophilia
dc.subjectOral-contraceptives
dc.subjectG20210a Mutation
dc.subjectGene Variant
dc.subjectGln Mutation
dc.titleCombined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución